MedTrace Logo

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

NCT02188017 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-08

No results posted yet for this study

Summary

An randomized trial of two maintenance doses of Acthar Gel for patients with chronic pulmonary sarcoidosis. Patients will be observed for 24 weeks of treatment.

Conditions

  • Sarcoidosis
  • Pulmonary Sarcoidosis

Interventions

DRUG

Acthar gel

Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert P Baughman, MD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-12-31
Completion
2017-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02188017 on ClinicalTrials.gov